Colaborations and projects I+D

	ORYZON is a partner in MIND, a multidisciplinary research project for the development and application of new technologies, to advance in the integral and personalized treatment of Alzheimer's disease, and other related dementias. The MIND Consortium consists of 12 companies and 35 public research centers, led by the company ERESA. The overall budget of the project is over 27 million Euros.
	ORYZON develop innovative medicines for Huntington's disease within the DENDRIA consortium: "Innovative solutions aimed at accelerating novel drug discovery and development for nervous system pathologies" which aims to implement new experimental and technological approaches in the searching for candidate compounds for the treatment of diseases of the Nervous System. DENDRIA Consortium consists of 12 companies and 24 research centers, led by the company Noscira S.A. The overall project budget is over 20 million Euros. www.dendria.es
	ORYZON participates with its partner Reig Jofre in the ONCOLOGICA Consortium: "New strategies based on biomarkers for cancer detection and prognosis, response prediction and the development of new drugs". The Consortium, led by the pharmaceutical company PhamaMar S.A., consists of eight Spanish biopharmaceutical and biotechnological companies and more than 20 research centers. The overall budget of the project is 17 million Euros. www.oncologica.es
	ORYZON is the LEADER in the ORYPRO project within the framework of European projects of the EuroTransBIO initiative. The project, carried out jointly with the Dutch company ProteoNic focuses on the development of new therapies for prostate cancer.
	ORYZON has received a grant of the ALZHEIMER DRUG DISCOVERY FOUNDATION (USA) for the development of new therapies for the disease of Alzheimer's disease based on epigenetics.
	ORYZON participates in the European FP7 project DDPDGENES: “Identification of genes important for human midbrain dopamine neuron development and Parkinson's disease” jointly with INBIOMED, Cambridge University, Karolinska Institutet and l' École Polytechnique Fédérale de Lausanne.
	ORYZON participates in the European FP7 REPRO-TRAIN: “Reproductive Biology Early Research Training network”. In this project, ORYZON carries out an epigenetic approach for developing new therapies for testicular cancer.